Interventional Cardiology Devices Market Size, Share, and Trends 2025 to 2034

Interventional Cardiology Devices Market Size and Forecast 2025 to 2034

The global interventional cardiology devices market size was estimated at USD 14.88 billion in 2024 and is anticipated to reach around USD 29.9 billion by 2034, expanding at a CAGR of 7.24% from 2025 to 2034. 

Interventional Cardiology Devices Market Key Takeaways

• North America dominated the global market with the largest market share of 45% in 2024.
• Europe is expected to grow with the highest CAGR during the forecast period.
• By product, the coronary stents segment captured the largest market share in 2024.
• By product, the intravascular imaging catheters and pressure guidewires segment is projected to witness the fastest CAGR during the forecast period.

What is the Role of AI in Interventional Cardiology Devices?

The advancements in AI technology has drastically the changed the overall healthcare sector. AI has been integrated in most of the medical fields for enhancing medical procedures and lowering the mistakes of healthcare professionals. Nowadays, the cardiology devices manufacturers have started adopting AI in their factories for enhancing the manufacturing process. AI can help in interventional cardiology by analyzing angiography images for transcatheter aortic valve implantation and valve placement. Moreover, AI helps in detecting the presence of heart diseases along with providing suitable methodologies for getting cured. 

• In September 2024, Viz.ai partnered with Cleerly. This partnership is done for developing an AI-based platform for diagnosing heart diseases.

U.S. Interventional Cardiology Devices Market Size and Growth 2025 to 2034

The U.S. interventional cardiology devices market size was evaluated at USD 4.69 billion in 2024 and is predicted to be worth around USD 9.59 billion by 2034, rising at a CAGR of 7.41% from 2025 to 2034.

North America dominated the global market with the largest market share of 45% in 2024. The presence of advanced healthcare infrastructure, favorable government product development initiatives, and high patient awareness levels, combined with relatively high healthcare expenses in the region, are some of the major drivers for the interventional cardiology devices market to grow. In North America, the U.S. is a major contributor of the market with presence of several market players such as Boston Scientific, Abbott Laboratories, Cardinal Health and some others. These market players are adopting several strategies such as product launches, acquisitions, partnerships and some others to maintain their dominance in the industry.

• In October 2024, Boston Scientific Corporation announced that the FDA had approved FARAWAV NAV Ablation Catheter. This catheter is used for the treatment of paroxysmal atrial fibrillation.

Europe is expected to grow with the highest CAGR during the forecast period. Europe has a high rate of premium-priced interventional cardiology devices consumption, and it is the region that can accommodate a high rate of medical device innovation, thereby dominating the interventional cardiology devices market. Also, the cases of peripheral artery disease has increased rapidly in Germany and France that in turn increases the demand for cardiology devices, thereby boosting the market growth. Moreover, several government initiatives aimed at advancing the cardiology department along with technological advancement in healthcare sector has boosted the growth of the interventional cardiology devices market in this region.

Market Overview

Interventional cardiology is a subspecialty of cardiology. Interventional cardiologists are cardiovascular diseases specialists who have completed training. They focus on the use of catheters, which are thin, flexible tubes used to execute procedures. Angioplasty and stenting, for example, are accomplished by directing equipment through the body’s arteries. These minimally invasive interventional techniques are an excellent alternative to open surgery for many individuals.

Interventional cardiology is concerned with the use of catheters to treat heart problems. The process entails inserting a device such as balloon, stent, catheter, or other device into femoral artery or any other big peripheral artery or vein, and then cannulating the heart under X-ray guidance. Furthermore, a variety of interventional cardiology devices are utilized to treat peripheral vascular problems that impact the circulatory system and can lead to plaque build-up in limb arteries. The catheters, balloons, stents, and filters are some of the interventional cardiology devices on the market.

Interventional Cardiology Devices Market Growth Factors

• The development of minimally invasive coronary stents.
• A large number of patients suffering from coronary heart diseases. 
• The rapidly growing elderly population.
• Increased patient awareness of cardiovascular diseases.
• The increasing need to monitor and treat patients. 
• The development of more advanced and innovative cardiovascular devices.
• Numerous government programs to increase the accessibility of IC treatments.
• Technological advancements in cardiology devices industry.

Market Scope

Market Dynamics

Driver

Rising Incidences of Ischemic Heart Disease 

The prevalence of ischemic heart disease has grown significantly in several countries such as the U.S., India, China and some others. It is usually caused by joining of fatty material and plaque inside the coronary arteries through a process called atherosclerosis. These diseases are caused by several factors such as smoking tobacco, obesity, high cholesterol, old-age, diabetes and some others. The interventional devices including angioplasty balloons, angioplasty stents, angioplasty catheters are found effective for treating this heart disease. Thus, the growing prevalence of coronary artery disease (CAD) has increased the demand for interventional cardiology devices, thereby boosting the industrial expansion.

According to American College of Cardiology, in 2023, ischemic heart disease was the leading cause of death with an age-standardized rate per 100,000 of 108.8 deaths.

Restraint

Presence of Alternatives 

The interventional cardiology devices industry experiences several problems. Firstly, there are several alternative techniques such as lipid-lowering drugs and anticoagulants that are highly effective for treating heart diseases, that in turn hampers the industry. Secondly, various market players have recalled their products due to their negative impact in the human body, thereby restraining the growth of the interventional cardiology devices market.

Opportunity

Adoption of Biosensors in Cardiology 

The application of biosensors has increased rapidly in the cardiology sector. In cardiology, these sensors are used for detecting cardiac biomarkers and measuring blood pressure. It also finds application in clinical analysis and diagnosis of several cardiac disorders. Also, the wearable biosensors are used for continuously monitor vital signs such as heart rate and pulse. Moreover, these sensors are capable of measuring pulse wave velocity for detecting the stiffness of arterial walls. Thus, the growing use of biosensors in cardiology is anticipated to create growth opportunities in the upcoming days.

Product Insights

The coronary stents segment held the largest share of the market. The rising demand for preventing heart attacks and strokes has driven the market growth. Also, these stents helps in curing problems such as chest pain and shortness of breath that is crucial for the industrial expansion. Moreover, the capacity of stents to improve blood flow and reduce the risk of re-narrowing along with the rapid adoption of minimally invasive surgical procedures has boosted the market growth.

• In May 2024, Abott launched XIENCE Sierra. XIENCE Sierra is an eluting coronary stent system that helps in curing patients suffering from blocked coronary arteries.

The intravascular imaging catheters and pressure guidewires segment is projected to witness the fastest CAGR during the forecast period. The growing demand for intravascular imaging catheters for diagnosing and treating heart conditions by delivering cross-sectional images of the heart and blood vessels has boosted the market growth. Also, the rising application of pressure guidewires in measuring blood pressure gradient and calculating fractional flow reserve (FFR) is driving the industrial expansion. Moreover, the rise in number of patients suffering from epicardial disease and coronary microvascular dysfunction has increased the demand for these devices, thereby driving the growth of the interventional cardiology devices market.

• In March 2024, Boston Scientific Corporation launched iCross. iCross is an imaging catheter that can provide detailed images of the heart and coronary arteries.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting different marketing strategies, such as new product launch, investments, partnerships, and mergers & acquisitions. The companies are also spending on the development of improved products. Moreover, they are also focusing on competitive pricing.

The various developmental strategies such as acquisition, business expansion, investments, new product launches, partnerships,joint venture, and mergers fosters market growth and offers lucrative growth opportunities to the market players. 

Interventional Cardiology Devices Market Companies

• Boston Scientific Corporation
• Medtronic
• Edward Lifesciences Corporation
• Abbott
• BIOTRONIK SE & Co. KG
• iVascular
• Terumo Corporation
• B. BarunMelsungen
• Biosensors International Group
• Cardinal Health

Recent Developments

• In September 2024, Argon Medical Devices launched CLEANER Vac. It is a thrombectomy system used to remove blood clot from the peripheral venous vasculature.
• In June 2024, Medtronic launched Steerant Aortic Guidewire. This device is used for facilitating catheter placement during interventional procedures in the aorta.
• In February 2024, BIOTRONIK joined hands with IMDS. This joint venture is done for launching micro Rx catheter used for interventional cardiac applications.

Segments Covered in the Report

By Product 

• Coronary Stents
  • DES
  • BMS
  • BRS
• PTCA Balloon Catheters
  • Normal
  • Specialty (Includes cutting, scoring, and lithotripsy balloons)
  • DCB
• Accessory Devices
  • PTCA Guidewires (Workhorse, Specialty)
  • Diagnostic Catheters
  • PTCA Guiding Catheters
  • Introducer Sheaths
• Intravascular Imaging Catheters and Pressure Guidewires (IVUS Catheters, OCT Catheters, FFR Guidewires)

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
• MEA
• Rest of the World